Lannett Co Inc (NYSE:LCI) is reporting fourth quarter earnings results on Wednesday 26th August 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.29 per share.
For the full year, analysts predict revenues of $ 542.11 million, while looking forward to income of $ 1.04 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 535.00 million ~ $ 545.00 million
Click Here For More Historical Outlooks Of Lannett Co Inc
Previous Quarter Performance
Lannett Co Inc announced income for the third quarter of $ 0.27 per share, from the revenue of $ 144.37 million. The quarterly earnings shrunk 60.29 percent while revenues fell 16.45 percent compared with the same quarter last year.
The consensus estimates are income of $ 0.29 per share from $ 134.52 million in revenue. The bottom line results missed street analysts by $ 0.02 or 6.9 percent, at the same time, top line results outshined analysts by $ 9.85 million or 7.32 percent.
Stock Performance
Shares of Lannett Co Inc traded high $ 0.17 or 2.86 percent on Tuesday, reaching $ 6.12 with volume of 430.50 thousand shares. The stock opened positive for the day at $ 5.97, after closing the previous day trading at $ 5.95.
According to the previous trading day, closing price of $ 5.95, representing a 21.68 % increase from the 52 week low of $ 4.89 and a 61.66 % decrease over the 52 week high of $ 15.52.
The company has a market capital of $ 246.95 million and is part of the Healthcare sector and Drug Manufacturers – Specialty & Generic industry.
Conference Call
Lannett Co Inc will be hosting a conference call at 4:30 PM eastern time on 26th August 2020, to discuss its 4Q20 financial results with the investment community. The participants may dial, 800-447-0521 Toll Free or 847-413-3238 Toll Number, with passcode : 49903262 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website lannett.investorroom.com/events-and-webcasts
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages.
